Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352189 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1HTTKDM4EMITF | |
| SCHEMBL5889359 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1HTTKDM4EMITF | |
| SCHEMBL7834588 | 0.91 | LDHA (0.50) | KDM4EALDH1A1LDHAMAPK1CYP1A2 | |
| SCHEMBL7830420 | 0.91 | LDHA (0.50) | KDM4EALDH1A1LDHAMAPK1CYP1A2 | |
| SCHEMBL5345318 | 0.89 | TAS1R3 (0.41) | TAS1R3TAS1R1HTTKDM4EMITF | |
| SCHEMBL29633689 | 0.84 | LDHA (0.47) | TAS1R3TAS1R1HTTKDM4EMITF | |
| SCHEMBL8064674 | 0.81 | CYP1A2 (0.39) | TAS1R3TAS1R1ALDH1A1LMNACYP1A2 | |
| SCHEMBL5889370 | 0.79 | HTT (0.50) | TAS1R3TAS1R1HTTALDH1A1LMNA | |
| SCHEMBL5351455 | 0.79 | HTT (0.50) | TAS1R3TAS1R1HTTALDH1A1LMNA | |
| SCHEMBL5355623 | 0.79 | HTT (0.50) | TAS1R3TAS1R1HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169808-B2 | Compounds useful for the preparation of medicaments with phosphodiesterase IV inhibitory activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-7169808-B2 | Compounds useful for the preparation of medicaments with phosphodiesterase IV inhibitory activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-7041703-B2 | 2-aminotetralines and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-05-09 | — | — | US | disclosed |
| US-6849663-B2 | 2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-02-01 | — | — | US | disclosed |
| US-20030229148-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-12-11 | — | — | US | disclosed |
| EP-1017667-B1 | 2-Amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA TAU IND FARMACEUTI (IT) | 2003-11-19 | — | — | EP | disclosed |
| US-20030158266-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-08-21 | — | — | US | disclosed |
| EP-0968174-B1 | OPTICALLY ACTIVE 2-AMINOTETRALINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, ACTIVE IN PREVENTING AND TREATING SEPTIC SHOCK | SIGMA TAU IND FARMACEUTI (IT) | 2003-01-22 | — | — | EP | disclosed |
| US-20020123652-A1 | 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A (IT) | 2002-09-05 | — | — | US | disclosed |
| US-6225501-B1 | S(-)-2-AMINO-6-FLUORO-7-METHOXYTETRALINE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-05-01 | — | — | US | disclosed |
| EP-1017667-A1 | 2-Amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-07-12 | — | — | EP | disclosed |
| EP-0968174-A1 | OPTICALLY ACTIVE 2-AMINOTETRALINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, ACTIVE IN PREVENTING AND TREATING SEPTIC SHOCK | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999015494-A1 | 2-AMINOTETRALINES, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998033762-A9 | OPTICALLY ACTIVE 2-AMINOTETRALINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, ACTIVE IN PREVENTING AND TREATING SEPTIC SHOCK | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998033762-A1 | OPTICALLY ACTIVE 2-AMINOTETRALINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, ACTIVE IN PREVENTING AND TREATING SEPTIC SHOCK | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123652-A1 | 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | AADAT, IL2, TPMT | TAS1R3 2342/4885TAS1R1 2672/4885HTT 1541/4885 |
| US-20030229148-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | AADAT, IL2, TPMT | TAS1R3 2501/4885TAS1R1 2729/4885HTT 1280/4885 |
| US-20030158266-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | AADAT, IL2, TPMT | TAS1R3 2501/4885TAS1R1 2729/4885HTT 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.